[Music] thank you welcome to CEO insights I'm Marilyn De Guzman with investing News Network I'm speaking with Geraldine Deli and cool Chief scientific officer of sirona biochem about an exciting new development of the company's proprietary TFC 1326 compound welcome Geraldine thank you pleasure to be there with you today yeah so I know that there's some uh some exciting news about the TFC 1326 but we before we get into that could you give us a backgrounder of what the TFC 1326 is and how it was developed


yes yes it's uh it's a long story but I will try to make it short as you know especially in drug Discovery we learn a lot from nature so I was as a scientist long time ago interested in antifreeze glycoprotein which is found in polar fish and allow them to survive at low temperature uh this compounds especially for natural compound are very unusual chemical structure which consists of repeating units of three amino acid and two saccharides like a polymeric natural compounds and it has an amazing properties of


protecting species against stress and especially against cold stress and cold damage and I start to find we start to work on this family of compounds sometimes ago and and we we try to mimic them in order to improve their stability and to build a library of compounds with a smaller size our intent at first was to develop the protective effect of this natural compounds and especially for different type of stress like oxidative stress so we built a portfolio of several compounds with which shows amazing


properties in cell protection against stress and 1326 was part of it it was obtained accidentally it shows that our intent was to produce another compounds and during the reaction process a secondary product was formed we spent some time to run experience to try to identify its chemical structure and and finally we were able to solve to solve it and uh and so the name of was given of 1326 but this compound has a slightly different chemical structure from the other one of the family and this small differentiation making


particularly attractive for cosmetic application because it can have a better permission within the skin so at first we evaluated on skin protection from cell protection like fibroblast protection against stress but also in genomic study it gives like all the compounds of the library very good results and between we decide to put it to put it further in in other in vitro essays for further evaluation and you have to keep in mind that in 80 percent of the Aging of the visible sign of Aging within the skin is due to external


stress so external factors such as oxidative stress UV pollution tobacco and there's visible sign of Aging include skin dryness include Jeweler skin fine line wrinkles and loose and sagging skin and and this is due to a decrease of lipid production within the skin a decrease of the collagen a decrease of the fat which is present in the deeper layer of the skin and this is all related to a specific chronic inflammatory states that occurs within the skin during aging so with this with this compound with the


first evaluation we were very pleased to have a protective effect because we so you solve a a huge part of the Aging of the visible sign of Aging that will occur within the skin thanks to that but in addition we observe that this family of compound and especially 1326 leads to an increase of lipid production which was an issue in the edging an increase of the collagen synthesis and increase also of the hyaluronic acid synthesis and a strong and an amazing reduction of the inflammation process so this give a huge opportunity for


these compounds to be developed and what was very surprising for us is that all the results that we obtain in the in vitro study translate very well in the clinical trial yes and then let's talk about that clinical trials you've recently released some highlights of that clinical trial can you talk about that yes we perform this clinical trial on 20 volunteers with a very simple formulation because the objective was to see the efficacy of the axis of 1326 itself so a simple formulation which


include one percent of 1326 applied twice a day from morning and evening during three months and and it leads to amazing results and improve of the skin Radiance by 25 a decrease of the oval um yeah the overall facial sagging by 14 percent a strong very strong decrease of inflam both inflammation and oxidation by 54 and an increase done the density of the skin by 20 by 37 percent sorry and and this result was really amazing because if you think about um what oxidation in the skin oxidation leads to chronic inflammation


and both of them at the May are the major contributor of skin aging or visible skin aging so if we solve that by reducing the inflammation we solve part of the dysfunction that occurs within the cells that lead also to a decrease of the skin density so we can solve all the issue of the skin aging on the process of the skin aging with this agent and it's really like if 1326 restore the cell and the tissue at a younger States a bit like a Rejuvenation cure so it makes them each render them at the


same level of efficacy when they was younger so it's what we saw amazing results and what maybe was the most impressive in the result was the picture where really you can see the Improvement on the skin Radiance of course and on the oval phase uh shape and and I think what was uh also very pleasant for us is that the dermatologists which follow the clinical trial told us that sure the people was very pleased by the result of course but they have which were particularly unusual people from their surrounding


which asked them what have you done you change something you did something on your face and and that was pretty amazing because usually it's something that is not as noticeable than that right that's very interesting so during the clinical trial how long did it take to get um these uh results I would say I I don't know before so the only thing that I know is after two months because we put a first the first step to run the analysis by the CMO at two months so during the first two months I don't know if there


was Improvement because nothing has been analyzed during this period so after two months we already see a big Improvement in the oxidative the inflammatory a little bit but of course it starts also by the oxidation and then oxidation leads to inflammation so oxidation was first greatly improved and then inflammation in the second part was greatly improved as a follow-up of this pathway and and the overall skin sagging was improved since the beginning so but not fun we didn't perform any analysis before two months so we don't


know in the first step but I think it takes time for this product to achieve its result because it have to to resolve all the oxidative issue all the inflammatory issue in order to restore the Cell at a younger state yeah that's definitely good news for uh people looking for some Anti-aging products yeah so what are the next steps right now so there is um different things ongoing we are conducting a process development in order to produce these compounds because it starts assures in the lab so on milligram stage


and after in ground stage in order to do the clinical trial so now we have a 500 grams production ongoing in with our partner in China so where he will solve the issue that you know usually occur in the development and uh and in the same time we have ongoing discussion with different partners that have shown interesting into this uh Compound on this family of compound also we also will um we have soon an event at the bio partnering in Boston where we also we share with other prospects best results


so in order to find a way to license at these companies we also think about some potentially maybe do another performing another clinical trial in order to maximize the value of this compounds by maybe putting other other options like for example looking at the neck what can be done on the neck or looking also at other wrinkles like the nasolabial fold or the the vertical line of of the lips to see if we can have some improvement also and some Plumping effect on this so this is something that we right now try


to figure out what could be uh on the next stage on that right so the ones that you've done is that um over now so the clinical trials that you've done that you've had results for is that still ongoing or no the one the one that we've done is finished now yeah so it will be maybe another one if um the the really the target is to maximize to maximize the value of the compounds to do a a very good licensing deal prefer all right well we'll certainly look forward to more news coming from


your company about this promising new compound thank you I hope soon thank you and thanks everyone join us again next time for another engaging conversation on CEO insight foreign [Music] thank you